Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer
Abstract Lung cancer remains one of the most common malignancies, and its brain metastases significantly worsen the prognosis for patients. Current treatments for lung cancer face many challenges, including poor drug accumulation and the inability to simultaneously control primary and metastatic tum...
Saved in:
| Main Authors: | Xianglei Fu, Yanbin Shi, Hang Wu, Yankun Zhang, Yingying Liu, Xiaoyu Wan, Xiangqin Chen, Jiamin Zhou, Shengnan Qiu, Xiaogang Zhao, Zhongxian Tian, Lian Li, Hengchang Zang, Guimei Lin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-58312-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer
by: Apoorva Daram, et al.
Published: (2024-11-01) -
Effects of Surface Charge of Inhaled Liposomes on Drug Efficacy and Biocompatibility
by: Jinniu Zhang, et al.
Published: (2025-03-01) -
c-MET Inhibition Reverses the Osimertinib Resistance in Lung Circulating Tumor Cell Clusters and Suppresses Metastasis
by: Zhipeng Zhang, et al.
Published: (2025-08-01) -
Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
by: Y. Uehara, et al.
Published: (2024-09-01) -
Liposomal delivery system/adjuvant for tuberculosis vaccine
by: Melika Moradi, et al.
Published: (2023-06-01)